Literature DB >> 25360389

Vascular hypercontractility and endothelial dysfunction before development of atherosclerosis in moderate dyslipidemia: role for nitric oxide and interleukin-6.

Vanessa Cavieres1, Karla Valdes1, Brayan Moreno1, Rodrigo Moore-Carrasco2, Daniel R Gonzalez3.   

Abstract

Atherosclerosis is a chronic disease that affects peripheral arteries and the aorta. Several inflammatory processes are required until the production of an atheroma. Before the atheroma appears, endothelial dysfunction is a key event. We hypothesized that endothelial dysfunction occurs in a mouse model of mild dyslipidemia, the mouse deficient in apolipoprotein E (apoE(+/-)). Using aortic rings preparation, we found that apoE(+/-) mice showed increased developed tension in response to KCl 60 mM when using a range a pre-loads from 0.5 to 2.0 grams (p = 0.038). Next, we tested the vasorelaxant capacity of apoE(+/-) aortas (pre-contracted with phenylephrine) in response to acetylcholine, an endothelium-dependent vasodilator. ApoE(+/-) aortas showed diminished vasorelaxation in a range of Ach concentrations (p = 0.0032). Next we assessed the levels of plasma NO metabolites, nitrite plus nitrate. These were significantly reduced, along with a significant decrease of the endothelial nitric oxide synthase in ApoE(+/-) mice. When we analyzed the morphology of the aortas in apoE(+/-) mice, these showed no signs of atheroma. In addition, we analyzed the levels of inflammatory cytokines, TNF-alpha, MCP-1 and interleukin 6 (Il-6). While TNF-alpha was similar in both groups, (18.3 ± 2 pg/mL in wild type vs. 17.5 ± 2 pg/mL in apoE(+/-)), MCP-1 was increased in ApoE deficient mice (71.5 ± 0.8 pg/mL in wild type vs. 85.1 ± 7.4 pg/mL in ApoE(+/-) mice, p = 0.006), along with IL-6 (24.7 ± 1.7 pg/ml in wild type vs. 47.1 ± 12.5 in ApoE mice, p = 0.0055). These results suggest that mild dyslipidemia produces a pro-inflammatory state, associated with diminished NOS and NO production, which produces endothelial dysfunction.

Entities:  

Keywords:  Atherosclerosis; apoE; eNOS; endothelial dysfunction; nitric oxide

Year:  2014        PMID: 25360389      PMCID: PMC4212886     

Source DB:  PubMed          Journal:  Am J Cardiovasc Dis        ISSN: 2160-200X


  22 in total

Review 1.  Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management.

Authors:  K Tziomalos; V G Athyros; A Karagiannis; D P Mikhailidis
Journal:  Nutr Metab Cardiovasc Dis       Date:  2009-10-14       Impact factor: 4.222

2.  Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin.

Authors:  J B Laursen; M Somers; S Kurz; L McCann; A Warnholtz; B A Freeman; M Tarpey; T Fukai; D G Harrison
Journal:  Circulation       Date:  2001-03-06       Impact factor: 29.690

3.  Chronic ET(A) receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice.

Authors:  Livius V d'Uscio; Matthias Barton; Sidney Shaw; Thomas F Lüscher
Journal:  Cardiovasc Res       Date:  2002-02-01       Impact factor: 10.787

4.  Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy.

Authors:  E Lindmark; E Diderholm; L Wallentin; A Siegbahn
Journal:  JAMA       Date:  2001-11-07       Impact factor: 56.272

5.  Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice.

Authors:  L V d'Uscio; T A Baker; C B Mantilla; L Smith; D Weiler; G C Sieck; Z S Katusic
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-06       Impact factor: 8.311

Review 6.  Endothelial dysfunction: a marker of atherosclerotic risk.

Authors:  Piero O Bonetti; Lilach O Lerman; Amir Lerman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-02-01       Impact factor: 8.311

7.  Coordinated endothelial nitric oxide synthase activation by translocation and phosphorylation determines flow-induced nitric oxide production in resistance vessels.

Authors:  Xavier F Figueroa; Daniel R González; Mariela Puebla; Juan P Acevedo; Daniel Rojas-Libano; Walter N Durán; Mauricio P Boric
Journal:  J Vasc Res       Date:  2013-11-05       Impact factor: 1.934

Review 8.  Inflammation in atherosclerosis: from pathophysiology to practice.

Authors:  Peter Libby; Paul M Ridker; Göran K Hansson
Journal:  J Am Coll Cardiol       Date:  2009-12-01       Impact factor: 24.094

9.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells.

Authors:  A S Plump; J D Smith; T Hayek; K Aalto-Setälä; A Walsh; J G Verstuyft; E M Rubin; J L Breslow
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

10.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E.

Authors:  S H Zhang; R L Reddick; J A Piedrahita; N Maeda
Journal:  Science       Date:  1992-10-16       Impact factor: 47.728

View more
  13 in total

1.  Protective effects of heparin on endothelial cells in sepsis.

Authors:  Jianqi Ma; Jinghui Bai
Journal:  Int J Clin Exp Med       Date:  2015-04-15

2.  Cardiac Ischemia Reperfusion Injury Following Instillation of 20 nm Citrate-capped Nanosilver.

Authors:  N A Holland; D P Becak; Jonathan H Shannahan; J M Brown; S A Carratt; Lsv Winkle; K E Pinkerton; C M Wang; P Munusamy; Don R Baer; S J Sumner; T R Fennell; R M Lust; C J Wingard
Journal:  J Nanomed Nanotechnol       Date:  2015-10-01

3.  Citreoviridin Enhances Atherogenesis in Hypercholesterolemic ApoE-Deficient Mice via Upregulating Inflammation and Endothelial Dysfunction.

Authors:  Hai-Feng Hou; Na Yuan; Qing Guo; Tao Sun; Cheng Li; Jian-Bao Liu; Qun-Wei Li; Bao-Fa Jiang
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

4.  The hypotensive effect of acute and chronic AMP-activated protein kinase activation in normal and hyperlipidemic mice.

Authors:  Fiona H Greig; Marie-Ann Ewart; Eilidh McNaughton; Josephine Cooney; Corinne M Spickett; Simon Kennedy
Journal:  Vascul Pharmacol       Date:  2015-07-18       Impact factor: 5.773

Review 5.  The protective effect of lipoic acid on selected cardiovascular diseases caused by age-related oxidative stress.

Authors:  Beata Skibska; Anna Goraca
Journal:  Oxid Med Cell Longev       Date:  2015-04-08       Impact factor: 6.543

6.  Protection from cigarette smoke-induced vascular injury by recombinant human relaxin-2 (serelaxin).

Authors:  Alessandro Pini; Giulia Boccalini; Maria Caterina Baccari; Matteo Becatti; Rachele Garella; Claudia Fiorillo; Laura Calosi; Daniele Bani; Silvia Nistri
Journal:  J Cell Mol Med       Date:  2016-02-24       Impact factor: 5.310

7.  High-Intensity Exercise Reduces Cardiac Fibrosis and Hypertrophy but Does Not Restore the Nitroso-Redox Imbalance in Diabetic Cardiomyopathy.

Authors:  Ulises Novoa; Diego Arauna; Marisol Moran; Madelaine Nuñez; Sebastián Zagmutt; Sergio Saldivia; Cristian Valdes; Jorge Villaseñor; Carmen Gloria Zambrano; Daniel R Gonzalez
Journal:  Oxid Med Cell Longev       Date:  2017-06-18       Impact factor: 6.543

8.  Thymoquinone Alleviates the Experimental Diabetic Peripheral Neuropathy by Modulation of Inflammation.

Authors:  Long Chen; Bing Li; Biqin Chen; Yiye Shao; Qiong Luo; Xiaohong Shi; Yinghui Chen
Journal:  Sci Rep       Date:  2016-08-22       Impact factor: 4.379

9.  Omega-3 Fatty Acid Supplementation Improves Endothelial Function in Primary Antiphospholipid Syndrome: A Small-Scale Randomized Double-Blind Placebo-Controlled Trial.

Authors:  Sheylla M Felau; Lucas P Sales; Marina Y Solis; Ana Paula Hayashi; Hamilton Roschel; Ana Lúcia Sá-Pinto; Danieli Castro Oliveira De Andrade; Keyla Y Katayama; Maria Claudia Irigoyen; Fernanda Consolim-Colombo; Eloisa Bonfa; Bruno Gualano; Fabiana B Benatti
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

Review 10.  TGFβ, smooth muscle cells and coronary artery disease: a review.

Authors:  Emma L Low; Andrew H Baker; Angela C Bradshaw
Journal:  Cell Signal       Date:  2018-09-15       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.